Tuesday, July 24, 2012

10:38 AM 7/24/2012 - "Psychiatric News and Times" bundle created by Mike Nova

10:38 AM 7/24/2012

"Psychiatric News and Times" bundle created by Mike Nova

Description: Review of profession oriented news and press
A bundle is a collection of blogs and websites hand-selected by your friend on a particular topic or interest. You can keep up to date with them all in one place by subscribing in Google Reader.
There are
11 feeds included in this bundle
  • Psychiatric News Alert
  • PsychiatryOnline |
  • Current News | psychiatry.org
  • Home | psychiatry.org
  • PsychiatryOnline | Topics | Forensic Psychiatry
  • PsychiatryOnline | Home
  • NIMH - Twitter
  • Twitter / APAPsychiatric
  • Clinical Psychiatry News
  • NIMH | Director’s Blog
  • Psychiatric Times

via Psychiatric News Alert by noreply@blogger.com (Psychiatric News Alert) on 7/24/12

Results from a phase 3 clinical trial of a once-promising new medication to treat Alzheimer's disease (AD) showed that the drug failed to improve either cognition or daily functioning. Pfizer is developing the drug along with the Janssen Alzheimer Immunotherapy division of Johnson & Johnson. The clinical trial tested bapineuzumab in 1,100 people with mild to moderate AD, all of whom have the ApoE4 gene, which has been shown to increase the risk of developing the disease. In a July 23 press release, Pfizer said that while the company was disappointed in the results, further studies of bapineuzumab are planned, and data from a clinical trial in about 1,300 AD patients who do not carry the ApoE4 gene will be available soon. The drug is an antibody that binds to beta-amyloid in the brain—that protein is widely believed to be a cause of AD. The companies expected bapineuzumab to destroy beta-amyloid deposits. Commenting on the study results, Samuel Gandy, M.D., director of the Center for Cognitive Health at Mount Sinai School of Medicine, told the New York Times that since the brain plaques likely develop years or even decades before symptoms appear, "All these symptomatic trials are 25 years too late. I'm not terribly disappointed and I'm not discouraged" by the bapineuzumab data.

Read much more about bapineuzumab and the search for an Alzheimer's treatment in Psychiatric News here and here.

(image: Molekuul.be/Shutterstock.com)
For previous news alerts, click here.

via Twitter / NIMHgov on 7/24/12
NIMHgov: Attending the #AIDS2012 Intl Conf this week? Don't miss this session about mental disorders and HIV/AIDS on tues eve http://t.co/tjfJoIyK

via Twitter / APAPsychiatric on 7/23/12
APAPsychiatric: RT @APP_Publishing: A Parasite Is Linked With Suicide Risk: In a large prospective study of some 46,000 women in which levels of ant... ...

via Clinical Psychiatry News on 7/23/12
There was a piece in last Sunday’s New York Times written by an oncology nurse...

via Psychiatric Times on 7/18/12
Research is needed on the hypervigilant Narcissistic Personality Disorder subtype, which has been largely understudied in spite of clinicians’ warnings that this is the most frequent presentation in patients.

via Psychiatric News Alert by noreply@blogger.com (Psychiatric News Alert) on 7/23/12

In a large prospective study of some 46,000 women in which levels of antibodies to the parasite Toxoplasma gondii were measured at childbirth, researchers linked infection with the parasite to suicide during the subsequent decade or so after they gave birth. The lead scientist was Marianne Pedersen, M.Sc., of Aarhus University in Denmark. The results were reported online this month in the Archives of General Psychiatry.

In a previous prospective study conducted with the same large cohort of women, and in which levels of antibodies to T. gondii were also measured at childbirth, Pedersen and her team linked infection with T. gondii to the subsequent development of schizophrenia. For more information about this study, see Psychiatric News.

(Image: Jubal Harshaw/Shutterstock.com)
For previous news alerts, click here.

via Twitter / APAPsychiatric on 7/23/12
APAPsychiatric: RT @APP_Publishing: Could Skin Cells Hold Answers to Alzheimer's?: Skin cells taken from patients with Alzheimer's disease can be re... ...

via Twitter / APAPsychiatric on 7/23/12
APAPsychiatric: Tips for Talking to Kids about #AuroraShooting http://t.co/Xc073CqH … via @APAHealthyMinds #Colorado #mentalhealth #grief #anxiety #mhsm

via Psychiatric News Alert by noreply@blogger.com (Psychiatric News Alert) on 7/23/12

Skin cells taken from patients with Alzheimer's disease can be reprogrammed into brain cells with the help of a particular stem cell research technique, Andrew Sproul, Ph.D., and colleagues at the New York Stem Cell Foundation reported at the Alzheimer's Association International Conference in Vancouver July 16. The reprogrammed cells can be used to explore the biology of Alzheimer's and for early-stage testing of potential Alzheimer's treatments, the scientists believe. One advantage of the technology, Sproul said, is that it can generate a nearly infinite supply of brain cells.

Other Alzheimer's advances were reported recently at a National Institutes of Health-sponsored Alzheimer's summit—notably, that results from three trials of experimental Alzheimer's drugs will be announced later this year. For more information about the search for weapons to fight Alzheimer's, see Psychiatric News.

(Image: leonello calvetti/Shutterstock.com)
For previous news alerts, click here.

via Clinical Psychiatry News by m.schneider@elsevier.com on 7/23/12
The Affordable Care Act provided $1.5 billion through September 2015 to the National Health Service Corps to train more primary care providers via scholarships and loan repayment assistance. In...

via Clinical Psychiatry News on 7/23/12
Illicit drug use is common among heavy cigarette smokers in the general population, but among outpatients with schizophrenia who are heavy smokers, it is most common in the first decade of illness,...

via Clinical Psychiatry News by michele.sullivan@elsevier.com on 7/23/12
VANCOUVER, B.C. – An investigational drug has shown promise in improving memory and cognition in patients with mild to moderate Alzheimer’s disease in a 6-month, randomized, placebo-controlled trial...

via Twitter / NIMHgov on 7/23/12
NIMHgov: Research opportunities: Participants needed for study on pediatric obsessive compulsive disorder #OCD http://t.co/LfBLjpSS

via Twitter / NIMHgov on 7/23/12
NIMHgov: RT @IACC_Autism: Upcoming IACC Conference Call and Webinar - July 27, 2012 - 10:00a.m. to 2:00p.m. Eastern time - More information @ htt ...

via Clinical Psychiatry News on 7/23/12
VANCOUVER, B.C. – Medical foods and supplements designed to support neural health and function may soon expand treatment options for common forms of dementia based on the results of two studies.
One...

via Twitter / NIMHgov on 7/23/12
NIMHgov: Youths with #autism lack options after high school, need better transition planning & services @nimhgov http://t.co/s6JTg0V0

via Clinical Psychiatry News on 7/23/12
The landmark Supreme Court decision upholding the constitutionality of the Affordable Care Act (ACA) means that states can take the brakes off their implementation of the law. At least two states –...

via Twitter / APAPsychiatric on 7/22/12
APAPsychiatric: APA Job Central Psychiatrists - Lone Star Circle of Care - Central Texas, TX: http://t.co/BtkMfvJw #job

via PsychiatryOnline | Home on 7/20/12

This post has been generated by Page2RSS

via Home | psychiatry.org on 7/20/12
Talking with Children about Tragedy
Tips for discussing the recent tragedy in Aurora, Colorado

This post has been generated by Page2RSS

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)